Gilead Sciences Gets CHMP Backing for Expanded Yescarta Use

By Colin Kellaher

Gilead Sciences Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Yescarta cell therapy for certain B-cell lymphoma patients.

The Foster City, Calif., biopharmaceutical company said the recommendation covers adults with diffuse large B-cell lymphoma and high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.

Gilead said it expects a decision from the European Commission, which generally follows the CHMP's advice, in the coming months, adding that approval would make Yescarta the first CAR T-cell therapy available in Europe for patients who don't respond to first-line treatment.

B-cell lymphoma makes up the vast majority of the blood cancer non-Hodgkin lymphoma.

Gilead last month said sales of Yescarta rose 66% in the second quarter to $295 million.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 16, 2022 07:39 ET (11:39 GMT)

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024